escription of historical facts are forward-lookingstatements that involve risks uncertainties assumptions and other factorswhich if they do not materialize or prove correct could cause NuVasive'sresults to differ materially from historical results or those expressed orimplied by such forward-looking statements. The potential risks anduncertainties relative to the proposed acquisition in

escription of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
which, if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those expressed or
implied by such forward-looking statements. The potential risks and
uncertainties, relative to the proposed acquisition, include, but are not
limited to: the risk that the parties may not consummate the transaction in
the expected timeframe or that intervening factors may cause the parties to
alter the terms (financial or otherwise) of the transaction; the risk that
NuVasive may not be able to achieve expected synergies and strategic
benefits from Osteocel or the acquired technology; the risk that NuVasive
will not be able to successfully integrate the acquired operations; the
risk that revenues or profits following the transaction will be lower than
expected; the risk that business disruption (including, without limitation,
difficulties in maintaining relationships with employees, customers,
clients or suppliers) is greater than expected following the transaction;
and the risk that NuVasive will not be able to acquire or produce a
sufficient supply of product following the transaction. Additionally, other
factors that could cause actual growth and results to differ materially
include, but are not limited to: the uncertain process of seeking
regulatory approval or clearance for NuVasive's products or devices,
including risks that such process could be significantly delayed; the
possibility that the FDA may require significant changes to NuVasive's
products or clinical studies; the risk that products may not perform as
intended and may therefore not achieve commercial success; the risk that
competitors may develop superior products or may have a greater market
position enabling more successful commercialization; the risk that
additional clinical data may call into question the benefits of NuVasi'/>"/>

(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...

... RICHMOND, Va., June 30 Insmed Inc. (Nasdaq: ... been added to the Russell 3000 Index following Russell Investments, ... indexes on June 26, 2009. Insmed was also added ... of Russell,s U.S. indexes captures the 4,000 largest U.S. stocks ...

... ... of a comprehensive global report on Prescription Drugs market. The global ... factors slowing down growth in the global prescription drugs market include ... of generics, falling drug costs, and fewer new drug approvals. On ...

... (Nasdaq: BSTC ), a biopharmaceutical company developing first ... to the Russell 3000 and Russell 2000 Indexes effective at ... The Russell family of U.S. indexes is reconstituted annually and ... U.S. equity market. , , The Russell 3000 Index ...

(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...

(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...

... Khalid Iqbal Lifetime Achievement Award" for its role as ... disease. The award ceremony was held yesterday (10:45 am ... International Conference (AAIC 2013)" in Boston (USA). Eva-Maria ... progress in Alzheimer,s research in the course of their ...

... avian H7N9 influenza that emerged in China this year have ... the infection, but testing for antiviral resistance can give misleading ... The authors of a study published in mBio , ... characterized viruses taken from the first person known to be ...

... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...